HIV ENVELOPE SPECIFIC DARPIN-BASED MICROBICIDE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 将HIV和SIV感染的有效体外抑制剂CD 4特异性DARPin 57.2注射到9只感染SHIV-RT的恒河猴中。DARPin结合的CD 4阳性细胞早在注射后30分钟就在外周血中检测到，直到24小时标记。DARPin 57.2在体内和体外结合各种表达CD 4的细胞类型，结合量与细胞表面上的CD 4的量成正比。DARPin 57.2在注射后24小时内从血浆中清除。我们证明了CD 4特异性DARPin可以在体内快速和选择性地结合其靶细胞，从而进一步研究DARPin技术的可能临床应用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. CD4-specific DARPin 57.2, a potent inhibitor of HIV and SIV infection in vitro, was injected into 9 rhesus macaques infected with SHIV-RT. DARPin-bound CD4-positive cells were detected in the peripheral blood as early as 30 minutes after the injection and until the 24 hour mark. DARPin 57.2 bound the various CD4-expressing cell types both in vivo and in vitro with the amount of binding directly proportional to the amount of CD4 on the cell surface. DARPin 57.2 was cleared from the plasma within 24 hours after injection. We demonstrate that the CD4-specific DARPin can rapidly and selectively bind its target cells in vivo, warranting further studies on possible clinical use of the DARPin technology.